INCLUSION CRITERIA

   - Histologically- or cytologically-confirmed nasopharyngeal carcinoma meeting the
   following criteria:

      - WHO type I, II, or III

      - Stage II to IVB disease (minimally T2a, N0, M0 or any T any, N1, M0)

      - Measurable disease, defined as ≥ 1 lesion that can be accurately measured in ≥ 1
      dimension as ≥ 20 mm by conventional techniques or as ≥ 10 mm by spiral CT scan

      - Prior diagnostic surgery(s) at the primary site or neck allowed provided there is
      still measurable disease present

      - Without known brain metastases

   - Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1

   - Life expectancy > 3 months

   - Absolute neutrophil count (ANC) ≥ 1,500/mm³

   - Platelet count ≥ 100,000/mm³

   - Total bilirubin ≤ 1.5 times upper limit of normal (ULN)

   - Aspartate aminotransferase (AST) / alanine aminotransferase (ALT) ≤ 2.5 times ULN

   - Creatinine ≤ 1.5 mg/dL or creatinine clearance ≥ 55 mL/min (NOTE: * Patients with
   creatinine > grade 1 but < grade 3, hearing loss ≥ grade 2, and peripheral neuropathy
   ≥ grade 2 are eligible provided they receive carboplatin in place of cisplatin
   throughout study treatment)

   - Hearing loss < grade 2. Hearing loss grade 2 or greater attributable to tumor
   obstruction, when the bone conduction in the audiogram is consistent with less than
   grade 2, is permissible for cisplatin. Hearing loss will be evaluated by hearing in
   the best ear. If hearing loss is grade 2, patients are still eligible but should
   receive carboplatin throughout the protocol instead of cisplatin.

   - Peripheral motor/sensory neuropathy < grade 2. If peripheral neuropathy is grade 2,
   patients are still eligible but should receive carboplatin throughout the protocol
   instead of cisplatin.

   - Fertile patients must use effective contraception prior to and during study treatment

EXCLUSION CRITERIA

   - Uncontrolled intercurrent illness including, but not limited to, any of the following:

      - Ongoing or active infection

      - Symptomatic congestive heart failure

      - Unstable angina pectoris

      - Cardiac arrhythmia

      - Psychiatric illness or social situations that preclude compliance with study
      requirements

      - Clinically-significant cardiovascular disease

      - Cerebrovascular accident within the past 6 months

      - Myocardial infarction or unstable angina within the past 6 months

      - New York Heart Association (NYHA) class II to IV congestive heart failure

      - Serious and inadequately controlled cardiac arrhythmia

      - Significant vascular disease (eg, aortic aneurysm, history of aortic dissection)

      - Clinically-significant peripheral vascular disease

   - History of allergic reaction attributed to compounds of similar chemical or biologic
   composition to docetaxel, cisplatin, carboplatin, fluorouracil, bevacizumab, or other
   agents used in this study

   - Known brain metastases

   - Concurrent combination antiretroviral therapy for HIV-positive patients

   - Prior chemotherapy or radiotherapy for nasopharyngeal carcinoma

   - Pregnant or nursing